Utama › Adenokarsinoma Esofagus › Iowa
Kajian klinikal Adenokarsinoma Esofagus di Iowa
5 kajian untuk Adenokarsinoma Esofagus sedang mencari peserta di lokasi di Iowa.
Bandar di Iowa
Teks kajian rasmi (Bahasa Inggeris)
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
- UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny
- Saint Anthony Regional Hospital, Carroll
- Mercy Hospital, Cedar Rapids
- dan 8 lagi
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Okt 2026 · NCT06203600mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
- Mary Greeley Medical Center, Ames
- McFarland Clinic - Ames, Ames
- UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny
- dan 12 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05677490A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- Local Institution - 0268, Iowa City
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07221149Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- University of Iowa Hospitals and Clinics, Iowa City
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT06324357Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Waukee
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT07431281Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.